Oncology Nursing News®

Register for a live broadcast to learn more about TRODELVY (sacituzumab govitecan-hziy) with Dr. Hope S. Rugo

Head and Neck Cancers

Expert Discusses Updates in Thyroid Cancer

Expert Discusses Updates in Thyroid Cancer

BY MARCIA BROSE, MD, PHD

FDA Approves Pembrolizumab for Esophageal Cancer Subgroup

FDA Approves Pembrolizumab for Esophageal Cancer Subgroup

BY BRIELLE BENYON

Oncology Nurses Are Key in Head and Neck Cancer Care

Oncology Nurses Are Key in Head and Neck Cancer Care

BY MICHAEL G. MOORE, MD

FDA Approves Pembrolizumab Regimens for HNSCC

FDA Approves Pembrolizumab Regimens for HNSCC

BY BRIELLE BENYON

Eliminating Gender-Based Barriers to Immunotherapy

Eliminating Gender-Based Barriers to Immunotherapy

BY KATIE KOSKO

Low-Dose Drug Regimen Is Effective for Older, Frail Patients With Gastroesophageal Cancer

Low-Dose Drug Regimen Is Effective for Older, Frail Patients With Gastroesophageal Cancer

BY BRIELLE BENYON

Twitter Lends Insight to HPV-Associated Oral Cancer Knowledge

Twitter Lends Insight to HPV-Associated Oral Cancer Knowledge

BY BRIELLE BENYON

Preventing Radiation Dermatitis

Preventing Radiation Dermatitis

BY RAYMOND CHAN, PHD, RN, BN, MAPPSC

Pembrolizumab Shows OS Benefit in PD-L1+ Esophageal Cancer

Pembrolizumab Shows OS Benefit in PD-L1+ Esophageal Cancer

BY GINA COLUMBUS

Nivolumab Extends Survival in Advanced or Recurrent Esophageal Cancer

Nivolumab Extends Survival in Advanced or Recurrent Esophageal Cancer

BY GINA COLUMBUS

External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc

OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives

About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.